ImmunoPrecise Antibodies Profit Margin

As of the most recent data (January 2026), IPA shows a profit margin of -66.38%. That compares with -192.17% in the prior-year period — up 65.5% year over year. That is below the Healthcare sector average of 14.34%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IPA's profit margin is now -66.38% (was -192.17%) — a 65.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether ImmunoPrecise Antibodies is outperforming or lagging.

The Healthcare sector average profit margin is about 14.34%. ImmunoPrecise Antibodies is at -66.38%, which is lower that average. That is roughly 562.8% below the sector mean. Use the comparison chart on this page to see how IPA stacks up against individual peers as well.

That compares with -192.17% in the prior-year period — up 65.5% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare ImmunoPrecise Antibodies with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has ImmunoPrecise Antibodies's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -66.38%) with ownership activity and broader fundamentals.